Opzelura

Opzelura (ruxolitinib (topical)) is a prescription medication used to treat Eczema and vitiligo. A prescription cream for mild-to-moderate eczema and for nonsegmental vitiligo, the first topical to help restore skin color in vitiligo.

A topical JAK inhibitor that calms the local immune signaling behind eczema inflammation and vitiligo pigment loss.

Commonly reported side effects of Opzelura include Application-site reactions, Acne, Itching, Possible serious infections, and Class warnings for blood clots and cancer. This is not a complete list — tell your doctor or pharmacist about any side effects you experience.

Yes. Opzelura carries an FDA Boxed Warning — the agency's most serious safety warning. Read the full prescribing information and talk to your doctor about the risks before starting or changing treatment.

The active ingredient in Opzelura is ruxolitinib (topical), which belongs to a class of medicines known as Topical JAK Inhibitor.

Opzelura is manufactured by Incyte. It was first approved in 2021.

You may be able to lower the cost of Opzelura by using a free pharmacy discount card or by comparing prices across pharmacies before you fill your prescription. Savings vary by pharmacy and location.